Trial Profile

A Phase I/II Clinical Study of WJ05129 Tablets in Patients With Locally Advanced or Metastatic Malignant Solid Tumors

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 26 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JS-112 (Primary) ; Paclitaxel (Primary)
Indications Advanced breast cancer; Gastric cancer; Gynaecological cancer; Neuroblastoma; Oesophageal cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Suzhou Junjing BioSciences

Most Recent Events

02 Oct 2025 Study arms increased to 2. Combination arm added newly.
02 Oct 2025 Status changed from not yet recruiting to discontinued.Reason the study was stopped: The sponsor terminated the study on the basis of the current data and the company's research and development strategy
15 Apr 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com